HO

Hoth Therapeutics IncNASDAQ HOTH Stock Report

Last reporting period 30 Sep, 2023

Updated 31 Oct, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

HOTH Stock Analysis

HO

Uncovered

Hoth Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.006

Dividend yield

Shares outstanding

1.44 B

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.

View Section: Eyestock Rating